Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is recognized for its efficacy in treating NSCLC patients harboring EGFR mutations and is preferred as a first-line treatment [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.